Stargardt Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Stargardt Disease Market Outlook

Thelansis’s “Stargardt Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Stargardt Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Stargardt Disease Overview

Macular dystrophy comprises a set of hereditary disorders characterized by retinal irregularities located between the temporal vascular arcades. Stargardt disease (STGD1) is the most frequent cause of juvenile macular dystrophy among these. It follows an autosomal recessive inheritance pattern, primarily linked to mutations in the adenosine triphosphate binding cassette transporter 4 (ABCR 4) gene. This genetic anomaly results in the accumulation of lipofuscin, a metabolic waste product, within the retina. The disease exhibits substantial heterogeneity in clinical manifestations, including variations in age of onset and progression rate. Patients experience a gradual decline in vision, usually commencing in their first or second decades of life. Presently, no approved treatments prevent or reverse visual deterioration in individuals with STGD1. Medical advice for patients centers on photoprotection to slow the disease's progression and provide low-vision aids for those with compromised visual fields. As the disease advances, many patients eventually reach legal blindness due to the loss of central vision, although peripheral vision often remains intact. The prognosis is highly variable and heavily contingent on the age of disease onset. Those with early onset typically face unfavorable outcomes, with a rapid decline in visual acuity, progressive retinal degeneration, and the potential development of profound chorioretinal atrophy. Consequently, individuals with this phenotype experience a severe form of the disease with a grim prognosis. In contrast, rapid-onset chorioretinopathy (ROC) represents a distinct sub-phenotype marked by swift disease progression. On the other hand, patients with late-onset disease typically maintain good visual acuity even into their later years. Fortunately, this condition does not significantly affect general health or life expectancy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: